590
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Otsuka's recently active trials. Comparator arms are excluded.
- SEP-3638566 trials
- AVP-7866 trials
- JNT-517 Tablet5 trials
- Aripiprazole5 trials
- Centanafadine5 trials
- Tolvaptan4 trials
Upcoming readouts
Next primary completion dates among Otsuka's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Oct 2026A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizoph…Phase 3
- May 2027QUANTUM-TB: A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuber…Phase 3
- Aug 2027A Long-term Trial of EB-1020 in Pediatric Patients With ADHDPhase 3
- Aug 2027A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHDPhase 2
- Nov 2027A Long-Term Study of JNT-517 in Participants With PhenylketonuriaPhase 3
- Dec 2027Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD PatientsPhase 2
Top therapeutic areas
Conditions studied most often across Otsuka's recently active trials.
- Schizophrenia17 trials
- Immunoglobulin A Nephropathy4 trials
- Phenylketonuria3 trials
- Major Depressive Disorder3 trials
- Atopic Dermatitis (AD)3 trials
- Keratoconjunctivitis Sicca2 trials
Otsuka trials
The 50 most significant of Otsuka's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term UseNCT05342493Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution | — | Not yet scored | OngoingRecruiting | 1,000 est. | 30 Sept 2026 |
| A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaNCT06894212SEP-363856 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 522 est. | 20 Oct 2026 |
| A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)NCT06799520VIS171 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 30 est. | 1 Dec 2026 |
| A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic DermatitisNCT07173478OPA-15406 | Phase 3 | Locked · track to reveal | OngoingNot yet recruiting | 156 est. | Dec 2026 |
| A Brain Imaging Study to Assess the Binding of MSP-2020 to Serotonin 5-HT2A Receptors in Healthy Male AdultsNCT07329621MSP-2020 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 18 est. | 29 Jan 2027 |
| A Trial to Examine if Repinatrabit is Processed Differently in Adults With Reduced Liver or Kidney Function Compared to Adults With Normal Liver and Kidney FunctionNCT07713758Repinatrabit | Phase 1 | Not yet scored | OngoingNot yet recruiting | 32 est. | 9 Feb 2027 |
| A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic DermatitisNCT07184645OPA-15406 | Phase 3 | Locked · track to reveal | OngoingNot yet recruiting | 198 est. | Feb 2027 |
| EnVISageA Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren'sNCT06928142Sibeprenlimab | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 83 est. | 13 Mar 2027 |
| QUANTUM-TBA Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary TuberculosisNCT07209761BPaQM | Phase 3 | Locked · track to reveal | OngoingRecruiting | 532 est. | 28 May 2027 |
| A Long-term Trial of EB-1020 in Pediatric Patients With ADHDNCT07087327EB-1020 (Centanafadine) low dose | Phase 3 | Locked · track to reveal | OngoingRecruiting | 180 est. | Aug 2027 |
| A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHDNCT07086313EB-1020 (Centanafadine) low dose | Phase 2 | Locked · track to reveal | OngoingRecruiting | 315 est. | Aug 2027 |
| A Study in Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus to Test the Effects of NDI-5001 Given for Multiple Days and to Test How NDI-5001 is Tolerated and Taken up in the BodyNCT07525960NDI-5001 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 24 est. | 25 Aug 2027 |
| REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)NCT06875986Brexpiprazole (Rexulti) | — | Not yet scored | OngoingRecruiting | 200 est. | 30 Sept 2027 |
| A Long-Term Study of JNT-517 in Participants With PhenylketonuriaNCT06628128JNT-517 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 240 est. | 1 Nov 2027 |
| A Long-term Trial of EB-1020 in Adult Patients With ADHDNCT06926829EB-1020 (Centanafadine) 164.4 mg | Phase 3 | Locked · track to reveal | OngoingRecruiting | 180 est. | Dec 2027 |
| Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD PatientsNCT06931080EB-1020 (Centanafadine) 164.4 mg | Phase 2 | Locked · track to reveal | OngoingRecruiting | 630 est. | Dec 2027 |
| A Study of JNT-517 in Participants With Phenylketonuria (PKU)NCT06971731JNT-517 Tablet | Phase 3 | Locked · track to reveal | OngoingRecruiting | 120 est. | 1 Mar 2028 |
| A Long-term Administration Trial of SEP-363856 in Patients With SchizophreniaNCT07225712SEP-363856 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 100 est. | Mar 2028 |
| A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)NCT04782258Tolvaptan Suspension | Phase 3 | Locked · track to reveal | OngoingRecruiting | 20 est. | 31 Jul 2028 |
| A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the BodyNCT07649265HBM7020 | Phase 1 | Not yet scored | OngoingNot yet recruiting | 63 est. | 20 Nov 2028 |
| Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)NCT05248659Sibeprenlimab 400 mg s.c. Q4weeks | Phase 2 | Locked · track to reveal | OngoingEnrolling by invitation | 600 est. | 28 Dec 2028 |
| LUPKYNIS Drug-use Results SurveyNCT07053891Voclosporin (LUPKYNIS) | — | Not yet scored | OngoingRecruiting | 400 est. | 30 Jun 2031 |
| A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered TogetherNCT07446400Repinatrabit | Phase 1 | Locked · track to reveal | OngoingRecruiting | 48 est. | 9 Jun 2026 |
| PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic SyndromesNCT06091267IV Decitabine | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 72 est. | 31 May 2026 |
| Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)NCT05248646Sibeprenlimab 400 mg | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 530 est. | 13 May 2026 |
| A Phase 2 Study of JNT-517 in Adolescent Participants With PhenylketonuriaNCT06637514JNT-517 Tablet | Phase 2 | Locked · track to reveal | Completed | 14 est. | 8 May 2026 |
| Samtasu Post-marketing General Drug Use-results Survey in Patients With Volume Overload in Heart Failure.NCT05712746Samtasu for I.V. infusion | — | Not yet scored | OngoingActive, not recruiting | 1,600 est. | 7 May 2026 |
| A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.NCT05279313Centanafadine Hydrochloride | Phase 3 | Locked · track to reveal | Completed | 680 est. | 24 Apr 2026 |
| P3b Short-term Study of CTN in Patients With ADHD and Comorbid AnxietyNCT06973577Centanafadine | Phase 3 | Locked · track to reveal | Completed | 315 est. | 22 Apr 2026 |
| A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male AdultsNCT0745508414C-SEP-380135 | Phase 1 | Locked · track to reveal | OngoingNot yet recruiting | 8 est. | 10 Apr 2026 |
| A Trial to Assess How Centanafadine Interacts With Stimulants in the BodyNCT07314333Centanafadine | Phase 1 | Locked · track to reveal | Completed | 40 est. | 30 Mar 2026 |
| A Study to Evaluate Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Multiple Doses of VIS954NCT06937593VIS954 | Phase 1 | Locked · track to reveal | Completed | 24 est. | 3 Feb 2026 |
| Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in SIADHNCT04790175Tolvaptan (SAMSCA) | — | Not yet scored | OngoingActive, not recruiting | 300 est. | 19 Jan 2026 |
| A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)NCT04786574Tolvaptan (OPC-41061) | Phase 3 | Locked · track to reveal | StoppedWithdrawn | 0 est. | 10 Dec 2025 |
| A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.NCT06143371CAN10 | Phase 1 | Locked · track to reveal | Completed | 80 est. | 10 Nov 2025 |
| A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive DisorderNCT05593029SEP-363856 | Phase 2 | Locked · track to reveal | Completed | 929 est. | 6 Nov 2025 |
| A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety DisorderNCT05729373SEP-363856 | Phase 2 | Locked · track to reveal | Completed | 434 est. | 26 Sept 2025 |
| A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive EpisodeNCT07549581SEP-380135 | Phase 1 | Locked · track to reveal | Completed | 43 est. | 12 Sept 2025 |
| First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With PhenylketonuriaNCT05781399JNT-517 Suspension | Phase 1 | Locked · track to reveal | Completed | 163 est. | 29 Jul 2025 |
| A Proof-of-concept Trial for OPC 131461 in Patients Hospitalized for Worsening Heart FailureNCT06795399OPC-131461 | Phase 2 | Locked · track to reveal | StoppedWithdrawn | 0 est. | 25 May 2025 |
| JUNIPERTrial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive DisorderNCT05536414Centanafadine | Phase 2 | Locked · track to reveal | Completed | 337 est. | 16 May 2025 |
| A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and WomenNCT07305779SEP-380135 | Phase 1 | Locked · track to reveal | Completed | 12 est. | 3 May 2025 |
| Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With SchizophreniaNCT03238326Brexpiprazole | Phase 3 | Locked · track to reveal | Completed | 295 est. | 22 Apr 2025 |
| A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCLNCT04049825OPB-111077 | Phase 1 | Locked · track to reveal | Completed | 36 est. | 25 Mar 2025 |
| Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With SchizophreniaNCT06036108OPC-34712FUM/ Brexpiprazole fumarate | Phase 1 | Locked · track to reveal | Completed | 59 est. | 18 Mar 2025 |
| A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)NCT05428033centanafadine capsule | Phase 3 | Locked · track to reveal | Completed | 574 est. | 17 Mar 2025 |
| How [14C]-JNT-517 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Male ParticipantsNCT07573449[14C]-JNT-517 | Phase 1 | Locked · track to reveal | Completed | 8 est. | 22 Jan 2025 |
| A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood LevelsNCT07253441CTN XR (TBM) | Phase 1 | Locked · track to reveal | Completed | 174 est. | 30 Dec 2024 |
| Samsca PMS in ADPKD PatientsNCT03406286Tolvaptan | — | Not yet scored | Completed | 2,067 est. | Dec 2024 |
| A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell LymphomaNCT04362007ASTX660 | Phase 1 | Locked · track to reveal | StoppedTerminated | 8 est. | 30 Nov 2024 |